{"id":578,"date":"2026-07-16T03:40:00","date_gmt":"2026-07-16T07:40:00","guid":{"rendered":"https:\/\/drugchatter.com\/insights\/?p=578"},"modified":"2026-05-21T23:12:24","modified_gmt":"2026-05-22T03:12:24","slug":"drug-brand-monitoring-has-a-blind-spot-ai-monitoring-fixes-it","status":"publish","type":"post","link":"https:\/\/drugchatter.com\/insights\/drug-brand-monitoring-has-a-blind-spot-ai-monitoring-fixes-it\/","title":{"rendered":"Drug Brand Monitoring Has a Blind Spot. AI Monitoring Fixes It."},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Pharmaceutical brand teams have spent decades building the infrastructure to know what the world says about their drugs. They pay IQVIA for prescribing data. They commission Kantar for brand health tracking. They run social listening programs against Twitter, Reddit, and patient forums. They fund physician survey panels, track adverse event reports, and watch competitor labeling updates like hawks.<\/p>\n\n\n\n

None of that infrastructure tells them what ChatGPT, Gemini, Claude, and Perplexity are saying about their drugs to the tens of millions of patients and physicians who ask those platforms every day.<\/p>\n\n\n\n

That gap between what traditional brand monitoring covers and what AI monitoring covers is large, growing, and, for commercially important brands, commercially significant. Pharmaceutical companies that treat AI monitoring as optional are accepting a blind spot in the most consequential new information channel in healthcare.<\/p>\n\n\n\n

This article makes the case that AI monitoring is not a standalone function but the logical next layer of brand monitoring \u2014 one that reads the same competitive landscape through a different lens, surfaces intelligence that traditional tools miss, and creates regulatory defensibility that is worth having before, not after, a problem surfaces.<\/p>\n\n\n\n

\n\n\n\n

What Traditional Pharma Brand Monitoring Actually Measures<\/strong><\/h2>\n\n\n\n

To understand what AI monitoring adds, it helps to be precise about what traditional brand monitoring does and does not capture.<\/p>\n\n\n\n

IQVIA’s National Prescription Audit covers approximately 93% of US outpatient dispensing data, giving brand teams near-real-time visibility into prescription volume, market share, prescriber-level trends, and payer mix. That is rearview mirror data \u2014 it tells you what happened weeks or months ago, after a physician made a prescribing decision. It does not tell you what influenced that decision.<\/p>\n\n\n\n

Kantar’s brand tracking programs measure brand awareness, consideration, and sentiment through surveyed physicians and patients. The data is methodologically rigorous and benchmarkable across time, but it captures declared attitudes in structured research settings, not real-world behavior in the moment of a treatment decision. Survey respondents give considered answers; patients querying AI systems at midnight about a drug they have just been prescribed do not.<\/p>\n\n\n\n

Social listening tools \u2014 IQVIA’s social media intelligence platform, Pulsar, Sprinklr, and similar products \u2014 track patient and HCP conversations across Reddit, X, patient forums, and condition communities. This gives genuine voice-of-customer intelligence and, at its best, early adverse event signals. But it captures what patients say about drugs. It does not capture what the system patients consult first is telling them about drugs.<\/p>\n\n\n\n

That is the gap. Traditional brand monitoring captures human-generated signals about drugs. AI monitoring captures what the primary automated information system is telling humans about drugs \u2014 and what those humans are asking it. The distinction matters because the AI’s characterization reaches an audience that dwarf any social media conversation, carries implicit authority that a Reddit post does not, and shapes decisions before traditional monitoring signals ever arrive.<\/p>\n\n\n\n

Why Brand Health Tracking Misses the AI Channel Entirely<\/strong><\/h3>\n\n\n\n

Brand health tracking is built around survey data \u2014 attitudinal measures of awareness, recall, trust, and intent captured in research settings. Those measures reflect what respondents consciously report about their perceptions. They do not reflect how those perceptions were formed, what information shaped them, or what automated systems contributed to them between the last brand team touchpoint and the survey.<\/p>\n\n\n\n

When a physician completes a brand tracking survey reporting favorable perceptions of a drug, that survey cannot tell the brand team whether an AI system’s inaccurate description of the drug’s dosing \u2014 encountered during a clinical lookup two weeks earlier \u2014 is subtly eroding the physician’s confidence in the drug’s safety profile. That erosion may not yet be visible in brand tracking. It will eventually show up in prescribing behavior. By the time it does, months of uncorrected AI misinformation have done their work.<\/p>\n\n\n\n

What IQVIA Social Media Intelligence Does Not Tell You About AI Drug Descriptions<\/strong><\/h3>\n\n\n\n

IQVIA’s social media intelligence platform is genuinely sophisticated. Its anti-obesity medication research has processed over 15 million online mentions related to GLP-1 therapies, offering brand teams granular insight into patient sentiment, treatment experience, and unmet need. That is real intelligence that shapes launch strategy and lifecycle management.<\/p>\n\n\n\n

But social media intelligence and AI monitoring answer different questions. IQVIA’s platform captures what patients are saying in public forums. AI monitoring captures what the AI system synthesized from those forums \u2014 and from clinical literature, news coverage, prescribing information discussions, and everything else in its training corpus \u2014 and is now telling the next 10,000 patients who ask about those drugs. The synthesis changes the information. It may strip caveats, overweight outlier experiences, introduce hallucinated clinical details, or favor one drug over another based on training data composition rather than clinical evidence.<\/p>\n\n\n\n

\n\n\n\n

The New Channel Pharma Cannot Afford to Ignore: LLM-Driven Health Queries<\/strong><\/h2>\n\n\n\n

The scale of the shift is documented and accelerating. One of the biggest trends in GenAI in 2025 was the massive shift of consumers seeking health information not from WebMD or Google, but from Gemini, ChatGPT, and other leading LLMs. Generative AI has permanently reshaped how health information is discovered, with AI platforms increasingly surfacing answers generated from a blend of user behavior and high-quality organic content on social media platforms like Meta, TikTok, and Reddit.<\/p>\n\n\n\n

Healthcare marketers at the AI Deciphered conference in 2025 described the year as a turning point for brand reputation management, with discovery patterns shifting from traditional search engines to LLM interactions. LLM-driven traffic is up 800% year-over-year and accelerating, according to Backlinko data. That trajectory has direct pharmaceutical implications.<\/p>\n\n\n\n

How Patients Now Discover Drug Information Through ChatGPT and Gemini<\/strong><\/h3>\n\n\n\n

The traditional pharmaceutical patient information pathway looked like this: diagnosis, prescription, patient package insert, follow-up appointment, perhaps an online search that landed on the manufacturer’s website or WebMD. The AI-mediated pathway is different: diagnosis, prescription, immediate conversational query to ChatGPT or Gemini, AI-generated answer that synthesizes clinical literature, patient forum content, and news coverage into a confident-sounding response. The follow-up appointment happens after the patient has already formed an AI-shaped view of their drug’s safety, efficacy, and alternatives.<\/p>\n\n\n\n

That AI-shaped view may be accurate. It may also contain incorrect dosing information, omitted black box warnings, off-label recommendations, or competitive framing that favors a different drug. The manufacturer has no visibility into any of it unless they are running systematic AI monitoring.<\/p>\n\n\n\n

What Happens When a Traditional Marketing Funnel Collapses Into One AI Conversation<\/strong><\/h3>\n\n\n\n

The traditional pharmaceutical marketing funnel \u2014 awareness, consideration, trial, adherence \u2014 operated across weeks or months, with touchpoints at each stage that brand teams could plan for and measure. AI has compressed that funnel. Panelists at the 2025 AI Deciphered conference explained that with AI, traditional marketing funnels are collapsing, with consumers cycling through awareness, consideration, and decision-making all in a single conversation with an LLM. In the health space, it is common for consumers to even receive unprompted product recommendations in their LLM conversations.<\/p>\n\n\n\n

A patient asking Claude about treatment options for their newly diagnosed condition may move from uninformed to treatment-selective in the same conversation, without visiting a manufacturer website, speaking with a pharmacist, or receiving a physician explanation. The AI shapes the entire decision arc. What it says about your drug in that single conversation matters more than any individual touchpoint in the traditional funnel.<\/p>\n\n\n\n

\n

‘AI is now the first place people go to for answers.’ \u2014 Jesse Wolfersberger, Global Lead of I\/O Health at Weber Shandwick, quoted in Fierce Pharma Marketing, September 2025.<\/p>\n<\/blockquote>\n\n\n\n

How Haleon’s GLP-1 Monitoring Strategy Demonstrates What Early Movers Are Doing<\/strong><\/h3>\n\n\n\n

Haleon \u2014 the consumer healthcare company that markets Advil and Sensodyne \u2014 spent 2025 establishing monitoring systems for LLM mentions. Kelly Kavanagh, Haleon’s US senior director of integrated marketing and media, described 2025 as ‘the year of the big aha. Like, guys, we got to start paying attention, really paying attention to what this dynamic of the AI world is bringing.’ Haleon tracks ‘share of mentions’ across LLM platforms, monitoring how brands appear in conversational AI responses rather than traditional keyword searches. The company has built custom agents \u2014 including one focused on GLP-1 medications \u2014 that the executive team tested in sessions where the CMO’s immediate response was: ‘Oh my god, we got a lot to do.’<\/p>\n\n\n\n

That reaction \u2014 from a senior executive who considered themselves well-informed about AI \u2014 captures where most of the pharmaceutical industry currently sits. The gap between awareness that AI matters for brand monitoring and active implementation of a monitoring program is wide. Companies closing that gap now are operating with a genuine information advantage over those that are not.<\/p>\n\n\n\n

\n\n\n\n

AI Share of Voice vs. Traditional Share of Voice: What Pharma Is Missing<\/strong><\/h2>\n\n\n\n

Share of voice is a well-understood concept in pharmaceutical marketing. Brand teams track it across paid search, earned media, HCP detail activity, and speaker programs. It tells you how prominent your drug is in the information environment relative to competitors. Most of those measurement systems have no AI dimension.<\/p>\n\n\n\n

How AI Share of Voice Is Calculated Across ChatGPT, Gemini, and Claude<\/strong><\/h3>\n\n\n\n

AI share of voice measures how often and how prominently a brand appears in AI-generated answers relative to competitors, across tracked query types and platforms. The calculation is conceptually simple: your drug’s mentions divided by total mentions of all drugs in your therapeutic category, expressed as a percentage, across all tracked platforms and query types. The operational challenge is that you need to run hundreds or thousands of structured queries across multiple platforms \u2014 at regular cadences \u2014 to generate data that is statistically meaningful and trackable over time.<\/p>\n\n\n\n

The same query asked to ChatGPT, Gemini, Claude, and Perplexity can produce substantially different answers in terms of which drugs are mentioned first, what side effects are emphasized, and how comparative claims are framed. A drug that leads in ChatGPT responses to clinical queries may appear third or fourth in Claude responses to identical queries. That ordering is not random \u2014 it reflects differences in training data, post-training alignment, and retrieval mechanisms. And it matters commercially, because first-mentioned drugs in AI comparative responses are more likely to be the drug a patient or physician mentally anchors on.<\/p>\n\n\n\n

Why LLM Share of Voice Diverges From Prescribing Share of Voice<\/strong><\/h3>\n\n\n\n

LLM share of voice and prescribing share of voice measure different things, and they can diverge significantly. A drug with strong prescribing share driven by favorable formulary placement, aggressive detailing, and payer rebate structures may still have low LLM share of voice if its clinical evidence base is thin relative to competitors, if patient forum sentiment about it is negative, or if its training corpus representation is weak. Conversely, a drug with an extensive peer-reviewed publication record and high media salience may have strong LLM share of voice that precedes and may eventually influence prescribing share.<\/p>\n\n\n\n

That divergence is an intelligence signal. A brand team that monitors both LLM share of voice and prescribing share of voice can detect situations where AI outputs are diverging from commercial performance \u2014 and investigate whether the divergence reflects a leading indicator of prescribing change or simply a training data artifact that corrective content strategy can address.<\/p>\n\n\n\n

How Do AI Platforms Handle Drug Comparisons Between Keytruda, Dupixent, and Opdivo?<\/strong><\/h3>\n\n\n\n

High-revenue oncology and immunology drugs compete in categories where AI-generated comparative responses carry genuine clinical stakes. Keytruda (pembrolizumab, $29.5 billion in 2024 global sales) and Opdivo (nivolumab, Bristol Myers Squibb’s competing PD-1 inhibitor) are described in clinical literature that goes back to their respective approval dates in 2014. Dupixent (dupilumab, top-tier immunology) and newer competitors like Skyrizi and Rinvoq compete in categories where treatment selection is nuanced and trial evidence is dense.<\/p>\n\n\n\n

An AI asked to compare pembrolizumab and nivolumab for non-small cell lung cancer will synthesize from clinical trial publications, meta-analyses, guideline recommendations, and clinical commentary \u2014 weighted by volume and recency in the training corpus, not necessarily by quality or relevance to the specific patient population the query is about. The AI’s comparative framing directly reflects what has been published and how prominently it was covered. A competitor that has published more real-world evidence, generated more guideline citations, or received more recent favorable coverage will tend to appear more favorably \u2014 regardless of relative clinical merit in any specific subpopulation.<\/p>\n\n\n\n

Does Generic Drug Substitution Get Recommended More Often in AI Responses?<\/strong><\/h3>\n\n\n\n

The generic substitution question is commercially sensitive and empirically answerable through AI monitoring. LLMs trained on cost-effectiveness literature, payer formulary discussions, consumer health sites, and patient forum advice threads carry a training-data weight toward recommending cost-effective alternatives \u2014 which often means generics or biosimilars \u2014 particularly in response to cost-related queries.<\/p>\n\n\n\n

A physician asking an AI system for ‘options for moderate-to-severe psoriasis’ will likely receive a response that includes both branded biologics and, depending on the platform, biosimilar alternatives weighted by their presence in the training corpus. For AbbVie, managing Humira’s biosimilar transition, what AI systems say when asked to compare adalimumab to its biosimilars is a commercial intelligence question with significant revenue implications. For Merck, whose Keytruda faces a biosimilar exposure horizon as its patents approach expiration, tracking how AI platforms characterize the branded versus biosimilar landscape is preparation intelligence.<\/p>\n\n\n\n

\n\n\n\n

What Brand Teams Discover When They First Run AI Queries About Their Drugs<\/strong><\/h2>\n\n\n\n

The experience of pharmaceutical brand teams running their first systematic AI queries about their own products tends to follow a predictable pattern. Initial queries produce results that are partially correct and partially alarming. The drug is described at roughly the right level of confidence. The indication language is close but not quite right. The dosing information may be off by enough to affect clinical decisions. The competitive framing places the drug in a position that does not match the brand team’s positioning.<\/p>\n\n\n\n

A DrugChatter audit of twenty branded drugs in 2024 found that 65% had at least one material factual error in AI-generated descriptions across four major platforms \u2014 wrong dosing information, incorrect indication language, outdated contraindication lists, or mislabeled routes of administration. Most brand teams conducting their first AI monitoring exercise find their own drug among the 65%.<\/p>\n\n\n\n

What Errors Appear Most Often When AI Describes Branded Drugs<\/strong><\/h3>\n\n\n\n

Four error types appear with the most commercial and regulatory significance.<\/p>\n\n\n\n